Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker KROS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | BlackRock Portfolio Management LLC | 1.81M | 9.1% | SCHEDULE 13G/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | BlackRock, Inc. | 1.67M | 8.4% | SCHEDULE 13G/A ↗ |
| Jul 17, 2026 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | BlackRock Portfolio Management LLC | 1.12M | 5.7% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Daniel Mack | 1.36M | 6.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Wilmot B. Harkey | 1.36M | 6.9% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Nantahala Capital Management, LLC | 1.36M | 6.9% | SCHEDULE 13G ↗ |
| Apr 7, 2026 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | BlackRock, Inc. | 1.99M | 10.1% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Tang Capital Partners International, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Tang Capital Partners, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Kevin Tang | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Tang Capital Management, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | David E. Shaw | 756,156 | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | D. E. Shaw & Co., L.L.C. | 755,473 | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | D. E. Shaw & Co., L.P. | 756,156 | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Eli Samaha | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Caraway Jackson Investments LLC | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Madison Avenue GP, LLC | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | EMAI Management, LLC | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Madison Avenue Partners, LP | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Madison Avenue International LP | 823,707 | 2.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | Michael Gelband | 13,360 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | ExodusPoint Capital Partners GP, LLC | 13,360 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | ExodusPoint Capital Management, LP | 13,360 | 0.0% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | KROS Keros Therapeutics, Inc. | The Vanguard Group | 1.53M | 5.0% | SCHEDULE 13G/A ↗ |
| Nov 18, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Michael Gelband | 1.91M | 6.3% | SCHEDULE 13G ↗ |
| Nov 18, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | ExodusPoint Capital Partners GP, LLC | 1.91M | 6.3% | SCHEDULE 13G ↗ |
| Nov 18, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | ExodusPoint Capital Management, LP | 1.91M | 6.3% | SCHEDULE 13G ↗ |
| Oct 27, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | David E. Shaw | 1.55M | 5.1% | SCHEDULE 13G ↗ |
| Oct 27, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | D. E. Shaw & Co., L.L.C. | 1.54M | 5.0% | SCHEDULE 13G ↗ |
| Oct 27, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | D. E. Shaw & Co., L.P. | 1.55M | 5.1% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Tang Capital Partners International, LP | 839,747 | 2.7% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Tang Capital Partners, LP | 1.58M | 5.2% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Kevin Tang | 2.42M | 7.9% | SCHEDULE 13G ↗ |
| Oct 22, 2025 | SCHEDULE 13G | KROS Keros Therapeutics, Inc. | Tang Capital Management, LLC | 2.42M | 7.9% | SCHEDULE 13G ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax Late Stage GP Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax Late Stage Fund L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax (China) IV, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax (Cayman) IV, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax (Israel) IV, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 16, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Pontifax Management 4 GP (2015) Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 15, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Daniel Schneeberger | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 15, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management GP, LLC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Oct 15, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 21, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | Daniel Schneeberger | 5.39M | 13.3% | SCHEDULE 13D/A ↗ |
| Aug 21, 2025 | SCHEDULE 13D/A (amended) | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management GP, LLC | 4.65M | 11.4% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances